Precision BioSciences advances hepatitis B gene-editing therapy PBGENE-HBV to Phase 2
DTIL•Precision BioSciences is advancing PBGENE-HBV into Phase 2 after Phase 1 results showed durable suppression of a viral marker and biopsy evidence of reductions in the persistent viral reservoir. Phase 2 dosing is expected in the first quarter of 2027, with initial open-label data anticipated in the second half.
1. Phase 2 plans
Precision BioSciences said it is advancing PBGENE-HBV, a gene-editing therapy for hepatitis B, into Phase 2 following encouraging Phase 1 results. The treatment showed durable suppression of a viral marker and biopsy evidence of reductions in the persistent viral reservoir. Safety was manageable, with no dose-limiting toxicities; no serious adverse events occurred at the selected Phase 2 dose. The company expects Phase 2 dosing to begin in the first quarter of 2027 and initial open-label data in the second half.
